Lou Vaickus, MD, FACP

louCHIEF EXECUTIVE OFFICER & FOUNDER

PERSONAL PROFILE

  • 35+ years in medicine and the pharmaceutical industry
  • 20+ years of executive pharma leadership

EXPERTISE
Physician Executive, Executive Leadership, Clinical Development and Medical Affairs, Preclinical Development, Regulatory Affairs/Quality Assurance, Business Development/Fundraising, Commercial Marketing, Medical Writing/Communications, and C-suite Activities.
Extensive experience at start-up, small-, medium-, and large-sized companies in all aspects of drug development and clinical medicine, including new chemical/molecular entities, biologics/biosimilars, cell therapies, devices, diagnostics, and assay development.
MD – Loyola University’s Stritch School of Medicine, with postdoctoral training in Immunology, Internal Medicine, and Hematology/Hematologic Malignancies at the Mayo Clinic and in Hematology/Oncology at Stanford University. Faculty – University of Iowa College of Medicine and SUNY Buffalo/Roswell Park Cancer Institute before joining industry in 1993.
Board-certified in Internal Medicine, Hematology/Hematologic Malignancies, and Medical Oncology.
Popular speaker at numerous events, with more than 60 peer-reviewed academic and industry-focused publications.
PROFESSIONAL EXPERIENCE – aktaPD

  • CEO and Founder, akta Pharmaceutical Development
  • Interim Chief Medical Officer – Antigen Activated T Cell Therapy Start-up
  • Interim Chief Medical Officer – Gene-altered Lymphocyte Cellular Therapy Start-up
  • Interim Chief Medical Officer – Vedanta Biosciences, Inc.
  • Interim Chief Medical Officer – Verastem, Inc.
  • Interim Chief Medical Officer – InVivo Therapeutics Corporation
  • Other consulting experience includes:

Preclinical Discovery and Clinical Development: RNAi interference technology. Privately-funded start-up.
Preclinical, Clinical, and IND Development: Proprietary in situ chemovaccination platform for anti-tumor immunity. Privately-funded start-up.
Phase 2/3 Study Design and Preclinical Development: Oncology/immunity biosimilar Mabs. Publicly-traded small biotech.
Independent Safety Evaluation Committee and Phase 1/2 Clinical Study: tRNA analog endogenous immunity and inflammation modulator. Rare muscle diseases/inflammatory myopathies. Privately-funded biotech with successful IPO.
Pre-IND/IND: Inhaled antifungals for CF, asthma, and pulmonary infections in ICH. Privately-funded biotech start-up.
Clinical Development Program: Peptide vaccine/diagnostic/device for immune tolerance in autoimmunity. Privately-funded, biotech start-up.
Pre-IND/IND/Ph 1: Genetically modified bacteria for ultra-rare metabolic diseases. Privately-funded, biotech start-up.
Medical Monitor, Clinical Development, Phase 1/2: Heparan sulfate mimetic. Oncology. Small, publicly-traded biotech.
Product Development: NCEs to modulate protein homeostasis and chaperones. Multiple indications including cystic fibrosis. Private start-up with successful IPO.
Diagnostics Development: Diagnostic platform technology in immune-regulated diseases to diagnose and monitor disease status and therapeutic response. Chronic and latent infectious diseases, oncology, autoimmunity, and inflammatory states. Small publicly-funded biotech.
Post-marketing Surveillance, Clinical Trials Transparency, Regulatory Affairs: NCEs in neuroscience, rare diseases, gastrointestinal, and internal medicine. Publicly-traded, large, specialty biotech.
Chief Development Officer/ Development Consultant: Privately-funded, venture capital, asset-centric development companies with two distinct products: GRAS nutritional and probiotics for immunological changes to gut microbiota in oncology and autoimmune indications.
Clinical Development Expert: Monoclonal antibodies for infectious disease indications. Privately-funded biotech.
Immunology Expert: BLA/MAA submission, oncology indication. Publicly-traded, small biotech.
 

Join Today

Curabitur arcu erat, accumsan id imperdiet et, porttitor at sem. Cras ultricies ligula sed dictum porta. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Curabitur non nulla sit amet nisl tempus convallis quis ac lectus. Curabitur arcu erat, accumsan id imperdiet et